Pharsight

Natesto generic

Natesto is a testosterone gel owned by Acerus and intended for nasal administration. The drug was first authorized for market on 28 May, 2014 and is delivered in metered nasal dosage forms.

When will Natesto generic be available?

The release of Natesto generics is anticipated after 17 March, 2034, following the expiration of its last patent.

Natesto uses

Natesto is used to treat conditions associated with a deficiency or absence of endogenous testosterone. It provides a unique method of testosterone replacement therapy by nasally administering an effective amount of the testosterone gel formulation.

Natesto patent expiration

Natesto is protected by 5 patents, with the final one expiring on 17 March, 2034. Once these patents expire, generic versions of Natesto may be released. Below are the details of the patents:

Natesto dosage

Want to ask something?